The Antithrombotic Potential of Dalteparin in Man Assessed Indirectly by Wessler’s Technique

Summary

The aim of this study was to demonstrate the effectiveness of a new experimental approach for assessing the antithrombotic potential of low molecular weight heparins (LMWH) such as dalteparin. In this approach, sera obtained from healthy volunteers treated with various i.v. doses of dalteparin (30, 60 or 120 anti-Xa IU/kg) or placebo (physiological saline) were used as the thrombogenic challenge in a Wessler’s stasis model of experimental venous thrombosis in the rat. Sera from placebo-treated volunteers showed a stable thrombogenic activity (0.25 ml/kg of serum producing thrombi of about 50 mg wet weight). Sera from healthy volunteers having previously received dalteparin however demonstrated dose- and time-related reductions in their thrombogenic activity. Half-lives of these effects were 300, 444 and >480 min for 30,60 and 120 anti-Xa IU/kg dalteparin respectively. These values were significantly higher than the corresponding anti-Xa and anti-IIa half-lives.

• References

• 1 Harenberg J. Relation of antifactor Xa activity of heparins and antithrombotic efficacity. Haemostasis 1988; 18 (Suppl. 03) 16-19
• 2 Ofosu FA, Blajchman MA, Modi GJ, Smith LM, Buchanan MR, Hirsh J. The importance of thrombin inhibition for the expression of anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulfate. Br J Haematol 1985; 60: 695-704
• 3 Pieters J, Lindhout T. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma. Blood 1988; 72: 2048-2052
• 4 Walenga JM, Bara L, Petitout M, Samama M, Fareed J, Choay J. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. Thromb Res 1988; 51: 23-33
• 5 Barrowcliffe TW, Merton RE, Havercroft SJ, Lindahl U, Thomas DP. Low affinity heparin potentiates the action of high affinity heparin oligosaccharides. Thromb Res 1984; 34: 125-134
• 6 Tew CJ, Lane DA, Thompson E, Ireland H, Curtis JR. Relationship between ex vivo anti-protease (factor Xa and thrombin) assays and in vivo anticoagulant effect of very low molecular weight heparin, CY 222. Brit J Haematol 1988; 70: 335-340
• 7 Wessler S, Morris LE. Studies on intravascular coagulation. IV. The effect of heparin and Dicoumarol on serum-induced venous thrombosis. Circulation 1955; 12: 553-556
• 8 Fareed J, Walenga JM, Kumar A, Rock A. A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin Thromb Hemost 1985; 11: 155-175
• 9 Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis model using different thrombogenic challenges. Thromb Res 1987; 46: 187-198
• 10 Van Ryn-McKenna J, Gray E, Ofosu FA, Buchanan MR. Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli. Thromb Haemost 1989; 61: 7-9
• 11 Millet J, Vaillot M, Theveniaux J, Brown NL. Experimental venous thrombosis induced by homologous serum in the rat. Thromb Res 1996; 81: 497-502
• 12 Millet J, Theveniaux J, Brown NL. The venous antithrombotic effect of LF 1351 in the rat following oral administration. Thromb Haemost 1992; 67: 176-179
• 13 Wessler S, Reimer SM, Sheps MC. Biologic assay of a thrombosis inducing activity in human serum. J Appl Physiol 1959; 14: 943-946
• 14 Hemker HC, Willems GM, Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56: 9-17
• 15 Jesty J. Analysis of the generation and inhibition of activated coagulation factor X pure systems and in human plasma. J Biol Chem 1986; 261: 8695-8702
• 16 Sandset M, Abilgaard U. Extrinsic pathway inhibitor. The key of feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 1991; 21: 219-239
• 17 Bara L, Bloch MF, Zittoun D, Samama M, Collignon F, Frydman A, Uzan A, Bouthier A. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res 1993; 69: 443-452
• 18 Hauptmann J, Kaiser B. Anticoagulant potential of synthetic and recombinant inhibitors of factor Xa and thrombin in vitro. Blood Coag Fibrin 1993; 4: 577-582
• 19 Buchanan MR, Boneu B, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to antithrombotic effects of heparin. Blood 1985; 65: 198-201
• 20 Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L, Lindahl U. Effects of heparin oligosaccharides with affinity for antithrombin III in experimental venous thrombosis. Thromb Haemost 1982; 47: 244-248
• 21 Breddin HK. Low molecular weight heparins’ state-of-the-art and unsolved issues. Blood Coag Fibrin 1993; 4: S17-S19
• 22 Monreal M, Silveira P, Monreal L, Monasterio J, Angles AM, Lafoz E, Lorente L. Comparative study on the antithrombotic efficacy of four low molecular weight heparins in three different models of experimental venous thrombosis. Haemostasis 1991; 21: 91-97
• 23 Mattsson CH, Palm M, Soderberg K, Holmer E. Antithrombotic effects of heparin oligosaccharides. In: Heparin and related polysaccharides. Structure and activities Ofosu FA, Danishefsky I, Hirsh J. eds Ann New York Acad Sci. 1989. 556 323-332
• 24 Dawes J, Bara L, Billaud E, Samama M. Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis 1986; 16: 116-122
• 25 Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama M. The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988; 28: 609-618
• 26 Briant L, Caranobe C, Saivin S, Sié P, Bayrou B, Houin G, Boneu B. Unfractionated heparin and CY 216: pharmacokinetics and bioavalabilities of the antifactor Xa and Ha effects after intravenous and subcutaneous injection in the rabbit. Thromb Haemost 1989; 61: 348-353
• 27 Ofosu FA. Pharmacology of unfractionated and low molecular weight heparins. In Low molecular weight heparins in prophylaxis and therapy of thromboembolic diseases Golhaber SZ, Bounameaux H. eds 1994: 1-20
• 28 Barbanti M, Calanni F, Milani MR, Marchi E, Semeraro N, Colucci M. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis evidence for an anticoagulant independent mechanism. Thromb Haemost 1993; 69: 147-151
• 29 Doutremepuich C, Llida S, Lalanne MC, Doutremepuich F. Modifications of biological activities of heparin and fraxiparine induced by the size and the age of a thrombus. Experimental study. Thromb Res 1990; 59: 439-447